{"prompt": "['FECD', 'PRODIGE', 'PARTENARIAT DE RECHERCHE', 'EN ONCOLOGIE DIGESTIVE', 'PRODIGE 59 - (FFCD 1707) - DURIGAST', 'A randomized phase II study evaluating FOLFIRI + durvalumab vs FOLFIRI +', 'durvalumab and tremelimumab in second-line treatment of patients with', 'advanced gastric or gastro-oesophageal junction adenocarcinoma', 'Randomized - non-comparative - multicenter phase II', 'N\u00b0 EudraCT : 2018-002014-13', 'An intergroup trial: FFCD - UNICANCER-GI - GERCOR', 'Principal investigator (FFCD):', 'Co-principal investigator (FFCD):', 'Pr. David Tougeron', 'Pr. Fr\u00e9d\u00e9ric Di Fiore', 'CHU de Poitiers', 'CHU Charles Nicolle', \"Service d'H\u00e9pato-gastro-ent\u00e9rologie\", \"Service d'Oncologie\", '2 Rue de la Mil\u00e9trie', '1 Rue Germont', '86021 POITIERS', '76031 ROUEN', 'FRANCE', 'FRANCE', 'Phone : +33 (0): 5 49 44 37 51', 'Phone : + 33 (0)2 32 88 86 10', 'Fax : +33 (0)5 49 44 48 60', 'Fax : +33 (0)2 32 88 86 69', 'Email : david.tougeron@chu-poitiers.f', 'Email : frederic.di-fiore@chu-rouen.fr', 'Co-principal investigator (GERCOR):', 'Co-principal investigator (UNICANCER GI):', 'Pr. Christophe Louvet', 'Dr. Farid El Hajbi', 'Institut Mutualiste Montsouris', 'Centre Oscar Lambret', '42 Boulevard Jourdan', \"D\u00e9partement d'oncologie g\u00e9n\u00e9rale\", '75014 PARIS', '3 Rue Fr\u00e9d\u00e9ric Combemale', 'FRANCE', 'BP 307- 59020 Lille CEDEX', 'Phone : + 33 (0)1 56 61 60 35', 'FRANCE', 'Fax : +33 + (0)1 56 61 69 60', 'Phone : + 33 (0)3 20 29 59 42', 'Email : christophe.louvet@imm.fr', 'Fax : +33 (0)3 20 29 55 00', 'Email : f-elhajbi@o-lambret.fr', 'COMMITTEE OF REDACTION :', 'David Tougeron (Poitiers, CHU), Fr\u00e9d\u00e9ric Di Fiore (Rouen, CHU), Karine le Malicot (Dijon, FFCD), Pierre Laurent-Puig', '(Paris HEGP), Fr\u00e9d\u00e9ric Bibeau (Caen, CHU), Christophe Louvet (Paris, Montsouris), Farid El Hajbi (Lille, CAC), Thierry', 'Lecomte (Tours, CHU), Thomas Aparicio (Paris, Saint-Louis), Astrid Li\u00e8vre (Rennes, CHU), Rosine Guimbaud (Toulouse,', 'CHU), Stefano Kim (Besan\u00e7on, CHU), Emilie Barbier (Dijon, FFCD), Sabrina Pierre (Dijon, FFCD), Daniel Gonzalez', '(Dijon, FFCD)', 'BIOLOGICAL COMMITTEE :', 'Pierre-Laurent Puig (Paris), David Tougeron (Poitiers), Fr\u00e9d\u00e9ric Di Fiore (Rouen), Fr\u00e9d\u00e9ric Bibeau (Caen), Thierry', 'Lecomte (Tours), Thomas Aparicio (Paris), Astrid Li\u00e8vre (Rennes), Harry Sokol (Paris)', 'SPONSOR AND DATA CENTER :', \"F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive (FFCD) - Facult\u00e9 de M\u00e9decine - 7, Boulevard Jeanne d' Arc - BP 87900\", '- 21079 Dijon Cedex - France', 'Executive director:', 'C\u00e9cile GIRAULT', 'T\u00e9l. : +33 (0)3 80 66 80 13 - Fax : +33 (0)3 80 38 18 41', 'Courriel : cecile.girault@u-bourgogne.fr', 'Statistician:', 'Karine LE MALICOT', 'T\u00e9l. : +33 (0)3 80 39 34 71- - Fax : +33 (0)3 80 38 18 41', 'Courriel : karine.le-malicot@u-bourgogne.fr', 'Project manager:', 'Lila GABA', 'T\u00e9l. : +33 (0)3 80 39 34 83 - Fax : +33 (0)3 80 38 18 41', 'Courriel : lila.gaba@u-bourgogne.fr', 'Confidential', 'This document is the property of the F\u00e9d\u00e9ration Francophone de Canc\u00e9rologie Digestive and may not be transferred, reproduced, published or used, in', \"whole or in part, without the federation's express authorization.\", 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 1 de 123']['TABLE OF CONTENTS', '1.', 'STUDY OBJECTIVE', '14', '1.1.', 'Safety run-in phases objectives', '14', '1.2.', 'Primary objective of phase II only', '14', '1.3.', 'Secondary objectives for phase II study', '14', '2.', 'PATIENT SELECTION ON REGISTRATION/RANDOMIZATION', '14', '2.1.', 'Inclusion criteria', '14', '2.2.', 'Non-inclusion criteria', '15', '3.', 'INCLUSION ASSESSMENT', '16', '4.', 'REGISTRATION/RANDOMIZATION.', '17', '5.', 'STUDY DESIGN', '18', '5.1.', 'Safety run-in', '18', '5.2.', 'Phase II study', '18', '6. TREATMENTS', '19', '6.1.', 'Description, packaging and labeling of durvalumab', '19', '6.2.', 'Description, packaging and labeling of tremelimumab', '20', '6.3.', 'FOLFIRI', '+', 'durvalumab (1st and 2nd steps of the safety run-in phase and Arm A)', '21', '6.4.', 'FOLFIRI + durvalumab + tremelimumab (2nd step of the safety run-in phase and Arm B)', '21', '7.', 'DOSE ADJUSTMENT BASED ON TOXICITY', '23', '7.1.', 'Criteria that must be met before each subsequent cycle (D1 of each cycle)', '23', '7.2.', 'Dose adjustment based on toxicities observed during the rest period', '23', '7.3.', 'Dose adjustment based on infusion-related reaction', '24', '7.4.', 'Dose adjustment of FOLFIRI', '24', '7.5.', 'Management of Immune-mediated adverse event (imAE)', '26', '7.6.', 'Partial treatments stop', '35', '7.7.', 'Premedications, concomitant treatments and contraindicated treatments', '36', '7.7.1.', 'Neutropenia', '36', '7.7.2.', \"Contraindicated treatments (see SmPCs and IB of each protocol's molecular entities)\", '36', '8.', 'LOGISTICS OF THE BIOLOGICAL STUDY (FOR PHASE II ONLY)', '36', '9.', 'PATIENT MONITORING', '37', '9.1.', 'During treatment', '37', '9.1.1.', 'Before each administration of treatment', '37', '9.1.2.', 'Evaluation every 8 weeks until radiological progression', '38', '9.2.', 'After treatment discontinuation', '38', '9.2.1.', 'Within 30 days for evaluating the toxicity of the last treatment', '38', '9.2.2.', 'After premature discontinuation of treatment other than for radiological progression*', '39', '9.2.3.', 'After treatment discontinuation because of radiological progression', '39', '10. SUBSEQUENT TREATMENTS', '39', '11. MANAGEMENT OF SERIOUS ADVERSE EVENTS', '39', '12. STATISTICAL ANALYSIS', '42', '12.1.', 'Safety analyses (safety run-in phase)', '42', '12.2.', 'Endpoints for phase II study', '42', '12.2.1.', 'Primary efficacy endpoint', '42', '12.2.2.', 'Secondary endpoints', '42', '12.3.', 'Sample size justification, statistical hypothesis', '43', '12.4.', 'Statistical analysis for phase II study', '44', '12.4.1.', 'Population definition', '44', '12.4.2.', 'Endpoint evaluation', '44', '13. STUDY COMMITTEES', '45', '13.1.', 'Independent data monitoring committee', '45', '13.2.', 'Steering committee', '45', '13.3.', 'Medical review', '45', '13.4.', 'Biological research committee', '45', '14. BACKGROUND INFORMATION AND RATIONALE FOR THE TRIAL', '46', '15. REFERENCES', '48', '16. ADMINISTRATIVE CONSIDERATIONS', '49', '17. RULES FOR PUBLICATION', '51', '18. APPENDICES', '51', 'APPENDIX 1: CLINICAL AND BIOLOGICAL INFORMED CONSENT', '52', 'APPENDIX 2: BIOLOGICAL STUDIES', '77', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 2 de 123']\n\n###\n\n", "completion": "END"}